CN102482255A - 用于合成吡非尼酮(pirfenidone)的改良方法 - Google Patents

用于合成吡非尼酮(pirfenidone)的改良方法 Download PDF

Info

Publication number
CN102482255A
CN102482255A CN2010800245047A CN201080024504A CN102482255A CN 102482255 A CN102482255 A CN 102482255A CN 2010800245047 A CN2010800245047 A CN 2010800245047A CN 201080024504 A CN201080024504 A CN 201080024504A CN 102482255 A CN102482255 A CN 102482255A
Authority
CN
China
Prior art keywords
pirfenidone
weight
molar ratio
solution
ratio computing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800245047A
Other languages
English (en)
Chinese (zh)
Inventor
罗马加丹·瑞哈克里斯纳
麦可·希尔
莎宾·玛莉-法兰西斯·布莉琪·布泰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102482255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CN102482255A publication Critical patent/CN102482255A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Cardiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2010800245047A 2009-06-03 2010-06-02 用于合成吡非尼酮(pirfenidone)的改良方法 Pending CN102482255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18358809P 2009-06-03 2009-06-03
US61/183,588 2009-06-03
PCT/US2010/037090 WO2010141600A2 (en) 2009-06-03 2010-06-02 Improved method for synthesizing pirfenidone

Publications (1)

Publication Number Publication Date
CN102482255A true CN102482255A (zh) 2012-05-30

Family

ID=43298478

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800245047A Pending CN102482255A (zh) 2009-06-03 2010-06-02 用于合成吡非尼酮(pirfenidone)的改良方法

Country Status (35)

Country Link
US (6) US20110003863A1 (https=)
EP (1) EP2440543B1 (https=)
JP (2) JP5848244B2 (https=)
KR (1) KR101734858B1 (https=)
CN (1) CN102482255A (https=)
AP (1) AP3630A (https=)
AR (1) AR076974A1 (https=)
AU (1) AU2010256693B2 (https=)
BR (1) BRPI1011015B8 (https=)
CA (1) CA2764043C (https=)
CL (1) CL2011003069A1 (https=)
DK (1) DK2440543T3 (https=)
EA (1) EA021826B1 (https=)
ES (1) ES2538103T3 (https=)
GE (1) GEP20156223B (https=)
HN (1) HN2011003187A (https=)
HR (1) HRP20150696T1 (https=)
HU (1) HUE026014T2 (https=)
IL (1) IL216565A (https=)
MA (1) MA33489B1 (https=)
MX (1) MX2011012654A (https=)
MY (1) MY162443A (https=)
NI (1) NI201100211A (https=)
NZ (1) NZ596872A (https=)
PE (1) PE20120398A1 (https=)
PL (1) PL2440543T3 (https=)
PT (1) PT2440543E (https=)
RS (1) RS54031B1 (https=)
SG (1) SG176648A1 (https=)
SI (1) SI2440543T1 (https=)
TN (1) TN2011000615A1 (https=)
TW (1) TWI434833B (https=)
UA (1) UA106759C2 (https=)
WO (1) WO2010141600A2 (https=)
ZA (1) ZA201108794B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598A (zh) * 2015-12-02 2016-02-17 新发药业有限公司 一种吡非尼酮的制备方法
CN112409246A (zh) * 2019-08-21 2021-02-26 北京凯因科技股份有限公司 一种新型吡非尼酮的晶型及其制备方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN107073112A (zh) * 2014-08-15 2017-08-18 皮克萨尔比奥公司 用于在患有脊髓损伤的对象中抑制炎症的组合物及其使用方法
EP3307714A1 (en) 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
ITUB20154832A1 (it) 2015-10-29 2017-04-29 Procos Spa Processo per la sintesi di pirfenidone
WO2017122139A1 (en) * 2016-01-14 2017-07-20 Laurus Labs Limited An improved process for the preparation of pirfenidone
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
WO2017130166A1 (en) * 2016-01-31 2017-08-03 Granules India Limited An improved process for the preparation of highly pure anti-fibrotic drug
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
IT201600071672A1 (it) * 2016-07-08 2018-01-08 Dipharma Francis Srl Metodo per sintetizzare un farmaco immunosoppressore
IT201600108927A1 (it) * 2016-10-27 2018-04-27 Dipharma Francis Srl Metodo per sintetizzare un farmaco antifibrotico
US20180009753A1 (en) * 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
WO2018083709A1 (en) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of pure 5-methyl-1-phenyl-2-1 (h)-pyridone
WO2018178996A1 (en) * 2017-03-28 2018-10-04 Natco Pharma Limited Improved process for the preparation of pirfenidone
WO2019028062A1 (en) 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
ES2886152T3 (es) 2017-12-11 2021-12-16 Laurus Labs Ltd Un procedimiento mejorado para la preparación de pirfenidona
JP7490813B2 (ja) * 2020-04-22 2024-05-27 ユンジン ファーム．カンパニー、リミテッド 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085858A1 (en) * 2001-04-20 2002-10-31 Asahi Glass Company, Limited Process for producing purified piperidine derivative
WO2003014087A1 (fr) * 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
CN1817862A (zh) * 2006-03-15 2006-08-16 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
WO2008147170A1 (es) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Nuevo proceso de síntesis para la obtención de 5-metil-1-fenil-2- (ih) -piridona, composición y uso de la misma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA2099868C (en) * 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
JP5587184B2 (ja) * 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085858A1 (en) * 2001-04-20 2002-10-31 Asahi Glass Company, Limited Process for producing purified piperidine derivative
WO2003014087A1 (fr) * 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
CN1817862A (zh) * 2006-03-15 2006-08-16 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
WO2008147170A1 (es) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Nuevo proceso de síntesis para la obtención de 5-metil-1-fenil-2- (ih) -piridona, composición y uso de la misma

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598A (zh) * 2015-12-02 2016-02-17 新发药业有限公司 一种吡非尼酮的制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
CN112409246A (zh) * 2019-08-21 2021-02-26 北京凯因科技股份有限公司 一种新型吡非尼酮的晶型及其制备方法
CN112409246B (zh) * 2019-08-21 2023-04-07 北京凯因科技股份有限公司 一种吡非尼酮的晶型及其制备方法

Also Published As

Publication number Publication date
PT2440543E (pt) 2015-07-03
AU2010256693B2 (en) 2015-09-17
US8519140B2 (en) 2013-08-27
AP3630A (en) 2016-03-08
US20120016133A1 (en) 2012-01-19
EP2440543A4 (en) 2012-11-21
EA201101695A1 (ru) 2012-05-30
BRPI1011015A2 (pt) 2018-02-14
CA2764043A1 (en) 2010-12-09
BRPI1011015B1 (pt) 2020-11-10
AU2010256693A1 (en) 2012-01-12
HRP20150696T1 (hr) 2015-08-28
MA33489B1 (fr) 2012-08-01
HUE026014T2 (en) 2016-05-30
WO2010141600A2 (en) 2010-12-09
SI2440543T1 (sl) 2015-06-30
BRPI1011015B8 (pt) 2021-05-25
MY162443A (en) 2017-06-15
KR101734858B1 (ko) 2017-05-12
EP2440543A2 (en) 2012-04-18
EP2440543B1 (en) 2015-04-15
US20150368200A1 (en) 2015-12-24
NZ596872A (en) 2013-12-20
US20140221660A1 (en) 2014-08-07
GEP20156223B (en) 2015-01-26
ZA201108794B (en) 2013-03-27
EA021826B1 (ru) 2015-09-30
HN2011003187A (es) 2015-02-02
PL2440543T3 (pl) 2015-09-30
AP2012006052A0 (en) 2012-02-29
NI201100211A (es) 2012-08-01
TW201043602A (en) 2010-12-16
JP5848244B2 (ja) 2016-01-27
RS54031B1 (sr) 2015-10-30
TWI434833B (zh) 2014-04-21
CA2764043C (en) 2018-01-16
MX2011012654A (es) 2012-01-12
ES2538103T3 (es) 2015-06-17
KR20120016277A (ko) 2012-02-23
CL2011003069A1 (es) 2012-05-25
JP2016026196A (ja) 2016-02-12
PE20120398A1 (es) 2012-05-13
IL216565A0 (en) 2012-03-01
US20150065720A1 (en) 2015-03-05
DK2440543T3 (en) 2015-05-18
WO2010141600A3 (en) 2011-04-21
SG176648A1 (en) 2012-01-30
AR076974A1 (es) 2011-07-20
TN2011000615A1 (en) 2013-05-24
UA106759C2 (uk) 2014-10-10
US20110003863A1 (en) 2011-01-06
IL216565A (en) 2015-06-30
US20130345430A1 (en) 2013-12-26
JP2012528877A (ja) 2012-11-15

Similar Documents

Publication Publication Date Title
TWI434833B (zh) 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法
AU2003284808B2 (en) The derivatives of pyridone and the use of them
KR102684529B1 (ko) 항미생물 화합물, 조성물, 및 그의 용도
US20060094883A1 (en) Process for preparing telmisartan
CN100475209C (zh) 抗冠状病毒剂
TW201309647A (zh) 鎵錯合物、藥學組成物及使用方法
HK1169109A (en) Improved method for synthesizing pirfenidone
JP2014503514A (ja) ガルシノール、シクロデキストリンの複合体およびその方法
OA16816A (en) Improved method for synthesizing pirfenidone
US20240207419A1 (en) SOLID FORM OF 2-CHLORO-2'-DEOXY-ADENOSINE COMPLEX WITH HPßCD
KR102921518B1 (ko) 니클로사마이드 및 피콜린산으로 이루어진 공결정, 이의 제조방법 및 이의 의학적 용도
CN101081860A (zh) 多烯类抗生素双酯化合物
US20230348354A1 (en) Polyaryl carboxylic fullerene derivative and use thereof in anti-coronavirus infection
KR20160035075A (ko) 치환체 벤질옥시 그룹 함유 에테르 화합물을 포함하는 항종양제.
HK1247726B (zh) 烟酰胺核苷的结晶形式

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1169109

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120530

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1169109

Country of ref document: HK